Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition

  • Multiple Sclerosis (MS)
Trial Status:


This trial runs in
  • Arganda del Rey
  • Barcelona
  • Castelló de la Plana
  • Córdoba
  • Girona
  • Lleida
  • Madrid
  • Móstoles
  • Pozuelo de Alarcón
  • San Cristóbal de La Laguna
  • Sant Joan Despí
  • Santander
  • València
  • Vigo
Trial Identifier:

NCT02598167 ML29715

      Show trial locations

      The source of the below information is the publicly available website It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This multi-center non-interventional, observational, cross-sectional study in adult participants with relapsing remitting multiple sclerosis (RRMS) will evaluate the participants' preferences for disease modifying treatments (DMT) in routine clinical practice.

      Hoffmann-La Roche Sponsor
      NCT02598167 , ML29715 Trial Identifier
      Multiple Sclerosis, Relapsing-Remitting Condition
      Official Title

      Assessing Patients Preferences Towards Disease-modifying Therapeutic Options in Relapsing Remitting Multiple Sclerosis

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participants aged greater than or equal to (>/=) 18 years
      • Participants who have a diagnosis of RRMS as documented in their medical records
      • Participants who have been prescribed a DMT for at least 3 months
      • Participants who have an expanded disability status scale (EDSS) score of 1-6 points
      Exclusion Criteria
      • Participants with any personal or medical condition that in opinion of the investigator would interfere with or make impossible proper participation in the study

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now